Switch theme
Sign up to access all valuation multiples
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
2015
2.9K+
LTM Revenue $1.3B
LTM EBITDA $285M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LivaNova has a last 12-month revenue (LTM) of $1.3B and a last 12-month EBITDA of $285M.
In the most recent fiscal year, LivaNova achieved revenue of $1.3B and an EBITDA of $203M.
LivaNova expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LivaNova valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Profit | $902M | XXX | $871M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $285M | XXX | $203M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $255M | XXX | $129M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $191M | XXX | $63.2M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $199M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, LivaNova's stock price is $43.
LivaNova has current market cap of $2.4B, and EV of $2.3B.
See LivaNova trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.4B | XXX | XXX | XXX | XXX | $3.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, LivaNova has market cap of $2.4B and EV of $2.3B.
LivaNova's trades at 1.8x EV/Revenue multiple, and 11.3x EV/EBITDA.
Equity research analysts estimate LivaNova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LivaNova has a P/E ratio of 12.4x.
See valuation multiples for LivaNova and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 11.3x | XXX | XXX | XXX |
| EV/EBIT | 9.0x | XXX | 17.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.4x | XXX | 37.3x | XXX | XXX | XXX |
| EV/FCF | 14.1x | XXX | 16.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLivaNova's last 12 month revenue growth is 6%
LivaNova's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
LivaNova's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LivaNova's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for LivaNova and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 183% | XXX | XXX | XXX |
| Rule of 40 | 9% | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LivaNova acquired XXX companies to date.
Last acquisition by LivaNova was XXXXXXXX, XXXXX XXXXX XXXXXX . LivaNova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was LivaNova founded? | LivaNova was founded in 2015. |
| Where is LivaNova headquartered? | LivaNova is headquartered in United States of America. |
| How many employees does LivaNova have? | As of today, LivaNova has 2.9K+ employees. |
| Who is the CEO of LivaNova? | LivaNova's CEO is Mr. Vladimir A. Makatsaria. |
| Is LivaNova publicy listed? | Yes, LivaNova is a public company listed on NAS. |
| What is the stock symbol of LivaNova? | LivaNova trades under LIVN ticker. |
| When did LivaNova go public? | LivaNova went public in 1993. |
| Who are competitors of LivaNova? | Similar companies to LivaNova include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of LivaNova? | LivaNova's current market cap is $2.4B |
| What is the current revenue of LivaNova? | LivaNova's last 12 months revenue is $1.3B. |
| What is the current revenue growth of LivaNova? | LivaNova revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of LivaNova? | Current revenue multiple of LivaNova is 1.8x. |
| Is LivaNova profitable? | Yes, LivaNova is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of LivaNova? | LivaNova's last 12 months EBITDA is $285M. |
| What is LivaNova's EBITDA margin? | LivaNova's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of LivaNova? | Current EBITDA multiple of LivaNova is 8.1x. |
| What is the current FCF of LivaNova? | LivaNova's last 12 months FCF is $163M. |
| What is LivaNova's FCF margin? | LivaNova's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of LivaNova? | Current FCF multiple of LivaNova is 14.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
